within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AB03_Afelimomab;

model Afelimomab
  extends Pharmacolibrary.Drugs.ATC.L.L04AB03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AB03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Afelimomab is a recombinant monoclonal antibody fragment (F(ab')2) directed against tumor necrosis factor-alpha (TNF-α). It was developed for the adjunctive treatment of sepsis and septic shock by neutralizing TNF-α-mediated inflammatory responses. Afelimomab is not currently approved or in therapeutic use, as clinical development was discontinued.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for adult subjects, based on typical monoclonal antibody fragment (F(ab')2) pharmaco-kinetics and publicly available summary data; no peer-reviewed publication with detailed human PK model available.</p><h4>References</h4><ol><li><p>Gallagher, J, et al., &amp; Velagapudi, R (2001). A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. <i>Intensive care medicine</i> 27(7) 1169–1178. DOI:<a href=\"https://doi.org/10.1007/s001340100973\">10.1007/s001340100973</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11534565/\">https://pubmed.ncbi.nlm.nih.gov/11534565</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Afelimomab;
